Litigation News

U.S. District Court ruled in favor of NeoGenomics, invalidating two core Natera patents (11,530,454 and 11,319,596) in their Minimal Residual Disease testing dispute. The court deemed Natera's patents invalid for claiming "ineligible subject matter" based on natural phenomena without demonstrating an "inventive concept." This overturns Natera's 2023 injunction against NeoGenomics' RaDaR v1.0 product, allowing NeoGenomics to commercialize its RaDaR ST assay and pursue CMS reimbursement. NeoGenomics' stock surged 18% following the ruling. Natera retains other patents but faces diminished IP protection and reported $100.9 million net loss partly from legal costs.

A Delaware jury ruled in favor of Globus Medical (NYSE: GMED) in a patent infringement case against Life Spine, Inc. The jury found Life Spine's Prolift implant line violated multiple claims of a Globus patent covering expandable spinal fusion technology. Globus was awarded both lost profits and reasonable royalty damages. The ruling affirms the validity of Globus's intellectual property in musculoskeletal innovation. Globus is also pursuing a separate lawsuit against Alphatec, Inc. involving expandable implant and retractor technologies, demonstrating the company's commitment to defending its patent portfolio in the competitive spinal implant market.

Eliza Labs filed a lawsuit against Elon Musk's xAI alleging monopolistic practices and attempted deplatforming of agentic AI launchpads. The suit claims xAI initially collaborated with Eliza Labs, inviting idea-sharing while Eliza built on xAI's free API. The relationship soured when xAI demanded $50,000 monthly for enterprise licensing or threatened legal action, despite Eliza already paying over $20,000 annually in fees. Eliza alleges xAI extracted technical documentation and usage data to copy their platform before attempting to banish them. The case highlights growing litigation in the AI sector over monopolistic practices and intellectual property rights.

Morrison Foerster secured summary judgment for NeoGenomics Inc. in the Middle District of North Carolina against Natera Inc.'s patent infringement lawsuit. Natera sued NeoGenomics in July 2023, claiming its RaDaR minimal residual disease assay infringed Natera's patents. The court previously issued a preliminary injunction removing the RaDaR assay from market. On August 28, 2025, Judge Catherine Eagles granted summary judgment invalidating all asserted patent claims under 35 U.S.C. § 101 for ineligible subject matter. The court will dismiss Natera's claims with prejudice and enter declaratory judgment of invalidity for both patents.

NeoGenomics Laboratory Inc. won summary judgment against Natera Inc.'s patent infringement lawsuit in the US District Court for the Middle District of North Carolina. Chief District Judge Catherine C. Eagles ruled that Natera's patents (US 11,519,035 and 11,530,454) covering cell-free DNA cancer-detection tests are invalid under patent eligibility standards. The court found the patents are directed at natural phenomena and lack inventive concepts, describing only "logical combinations" of "standard, well-known techniques" using off-the-shelf products, applying the Supreme Court's 2014 two-step patent eligibility test.

NeoGenomics won summary judgment against Natera in patent infringement litigation in the U.S. District Court for the Middle District of North Carolina. The court ruled that all of Natera's asserted patent claims are invalid for claiming ineligible subject matter and will dismiss Natera's claims with prejudice while entering declaratory judgment of invalidity for both patents. The ruling allows NeoGenomics to continue commercializing its RaDaR ST molecular residual disease assay without restriction. NeoGenomics has launched the assay to biopharma customers and submitted it for CMS reimbursement coverage.

A Delaware jury ruled in favor of Globus Medical in patent infringement litigation against Life Spine, finding that Life Spine's Prolift family of implants infringed valid Globus patent claims for expandable spinal fusion implants. The jury awarded Globus both lost profits and reasonable royalty damages. Globus has separate pending patent litigation against Alphatec involving expandable implant and retractor technology. The verdict affirms Globus's intellectual property rights in expandable spinal implant innovations and demonstrates the company's commitment to enforcing its patents against unauthorized use of its technology.

Alpha Modus Holdings Inc. filed a patent infringement lawsuit against Cooler Screens, Inc. in the U.S. District Court for the Northern District of Illinois (Case No. 1:25-cv-10004). The complaint alleges Cooler Screens' digital smart display systems infringe Alpha Modus's patents for in-store consumer engagement and analytics technologies. This follows Alpha Modus's recent confidential settlements with Kroger and Walgreens over their Cooler Screens technology deployments. Alpha Modus, a NASDAQ-listed AI-powered retail engagement company, asserts its intellectual property rights in retail display systems and seeks to ensure market compliance with its patented innovations.

Alpha Modus Holdings Inc. reached a confidential settlement with Walgreens in patent infringement lawsuit Alpha Modus, Corp. v. Walgreen Co. filed in U.S. District Court for the Eastern District of Texas (Case No. 2:25-cv-00120). The case involved Alpha Modus's U.S. Patent Nos. 10,977,672 and 11,042,890 related to in-store technology. The lawsuit will be dismissed with prejudice. Alpha Modus, which trades on NASDAQ as AMOD and develops AI-powered retail technology, stated this settlement reflects its IP monetization strategy and continues pursuing licensing and litigation opportunities involving its patented technologies.